JAK抑制剂血栓栓塞事件:基于FAERS的药物警戒研究
本研究基于FDA不良事件报告系统2012年1月至2021年9月数据,采用比例失衡分析(ROR与IC)评估JAK抑制剂与血栓栓塞事件的关联。共检测到15个阳性安全信号,涉及芦可替尼、托法替布、巴瑞替尼、乌帕替尼和菲戈替尼,部分信号需更多医学证据验证。
要点
- 巴瑞替尼与深静脉血栓(ROR025=8.27)和肺栓塞(ROR025=7.90)信号较强。
- 芦可替尼与门静脉血栓显著关联(ROR025=3.49)。
- 托法替布、乌帕替尼和菲戈替尼也显示血栓栓塞相关信号。
核心结论
- JAK抑制剂与多种血栓栓塞事件存在阳性安全信号,部分信号需更多医学证据验证。
研究设计与样本
- 基于FAERS数据库2012年1月1日至2021年9月30日数据的比例失衡分析,计算报告比值比(ROR)和信息成分(IC)。
主要发现
- 共检测到15个阳性安全信号,涉及8种已上市JAK抑制剂。
- 芦可替尼与门静脉血栓显著关联(ROR025=3.49,IC025=1.50)。
- 托法替布速释剂与肺栓塞(ROR025=2.09,IC025=1.02)和血栓形成(ROR025=1.15,IC025=0.18)相关。
- 巴瑞替尼与深静脉血栓(ROR025=8.27,IC025=3.00)、肺栓塞(ROR025=7.90,IC025=2.94)等多种血栓事件相关。
- 乌帕替尼与肺栓塞(ROR025=1.25,IC025=0.25)、肺血栓(ROR025=5.32,IC025=2.33)和血栓形成(ROR025=2.72,IC025=1.39)相关;菲戈替尼与肺栓塞(ROR025=4.83,IC025=2.10)相关。
局限性
- 部分安全信号仍需更多医学证据验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: As a new type of drug developed rapidly in recent years, Janus kinase inhibitors (JAKinibs) have caused controversy due to possible adverse reactions of thromboembolism. The aim of this study was to analyse and evaluate the association between thromboembolic events and the use of JAKinibs, on the base of the latest data in the Food and Drug Administration's Adverse Event Reporting System. METHODS: A disproportionality analysis was conducted, utilizing data from 1 January 2012 to 30 September 2021 in the FAERS. For each drug-adverse event pair, reporting odds ratio (ROR) and information components (IC) were calculated. RESULTS: A total of 15 positive safety signals were detected within the FAERS: ruxolitinib was significantly associated with portal vein thrombosis (ROR025 = 3.49, IC025 = 1.50); tofacitinib immediate release with pulmonary embolism (ROR025 = 2.09, IC025 = 1.02) and thrombosis (ROR025 = 1.15, IC025 = 0.18); tofacitinib extended release with pulmonary embolism (ROR025 = 1.27, IC025 = 0.26) and thrombosis (ROR025 = 1.29, IC025 = 0.33); baricitinib with deep vein thrombosis (ROR025 = 8.27, IC025 = 3.00), portal vein thrombosis (ROR025 = 1.97, IC025 = 0.63), pulmonary embolism (ROR025 = 7.90, IC025 = 2.94), thrombosis (ROR025 = 2.04, IC025 = 0.93) and venous thrombosis (ROR025 = 2.15, IC025 = 0.81); upadacitinib with pulmonary embolism (ROR025 = 1.25, IC025 = 0.25), pulmonary thrombosis (ROR025 = 5.32, IC025 = 2.33) and thrombosis (ROR025 = 2.72, IC025 = 1.39); and filgotinib with pulmonary embolism (ROR025 = 4.83, IC025 = 2.10). In the analysis of the time to onset of thromboembolic events, no obviously recognizable pattern was found. Several safety signals with embolic and thrombotic events (Standardised MedDRA Query) were found in the study. CONCLUSION: This pharmacovigilance study covered 8 types of JAKinib that are already on the market, and provided new safety signals based on past safety information. Some of these signals still need more medical evidence.
引用
- Dong Z, Ye X, Chen C, et al. Thromboembolic events in Janus kinase inhibitors: A pharmacovigilance study from 2012 to 2021 based on the Food and Drug Administration's Adverse Event Reporting System. Br J Clin Pharmacol. 2022. PMID: 35466415. doi:10.1111/bcp.15361
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。